Intrapleural Recombinant IL-2 in Passive Immunotherapy for Malignant Pleural Effusion

This publication has 30 references indexed in Scilit:

• Lymphokines and cytokines as cancer treatment.Immunotherapy realized
  Cancer, 1990
• A phase I study of interleukin-2 in children with cancer and evaluation of clinical and immunologic status during therapy. A pediatric oncology group study
  Cancer, 1989
• Lysis of Human Malignant Mesothelioma Cells by Natural Killer (NK) and Lymphokine-activated Killer (LAK) Cells
  American Review of Respiratory Disease, 1989
• Asbestos and Cancer: Human Natural Killer Cell Activity is Suppressed by Asbestos Fibers but Can Be Restored by Recombinant lnterleukin-2
  American Review of Respiratory Disease, 1989
• Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.
  Journal of Clinical Oncology, 1988
• Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer
  New England Journal of Medicine, 1987
• High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated Cancer
  JAMA, 1986
• Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.
  The Journal of Experimental Medicine, 1985
• Malignant mesothelioma 1982: Review of 4710 published cases
  Respiratory Medicine, 1983
• Carcinomatous involvement of the pleura
  The American Journal of Medicine, 1977